Senseonics Revenue Jumps 140%, Raises Outlook

The medical device maker's third-quarter revenue beat analyst expectations on strong demand for its Eversense 365 implantable glucose monitor.

Updated on Nov. 10, 2026 in Economic Indicators

Clean photograph of unlabeled white and stainless-steel precision instruments on a production bench, with a small sensor-shaped component at the center.
Senseonics reported third-quarter revenue of $19.56 million, up about 140% from a year earlier, and raised its fiscal 2026 revenue outlook to $68 million to $70 million. AI Illustration. Upload story photo >

Senseonics Holdings reported third-quarter revenue of $19.56 million, up about 140% from a year earlier and above analyst expectations of $16.20 million. The company also raised its fiscal 2026 revenue outlook to $68 million to $70 million.

Why it matters

Demand for Eversense 365 drove the beat, with U.S. revenue growing about 160% to $16.8 million and gross margin expanding to roughly 62% from 43% a year earlier. The raised guidance marks the third upward revision this year, signaling sustained momentum for the company's implantable continuous glucose monitor.

Senseonics posted a quarterly loss of 50 cents per share even as revenue topped analyst forecasts, with gross margin expanding to roughly 62% from 43% a year earlier. Analysts forecast fiscal 2026 revenue of $64.243 million, below the newly raised company outlook.

The players

Senseonics Holdings

Senseonics Holdings is a medical technology company that develops implantable continuous glucose monitoring systems, including the Eversense line, and trades on the NASDAQ under the ticker SENS.

Raymond James

Raymond James is a U.S. diversified financial services firm whose equity research division issues stock ratings and price recommendations on publicly traded companies.

Barclays

Barclays is a British multinational investment bank whose analysts publish price targets and ratings on equities, including medical device companies.

Stifel

Stifel Financial is a U.S. investment bank and wealth management firm whose research analysts issue ratings and price targets on publicly traded stocks.

The details

Strong sales of Eversense 365, the company's implantable continuous glucose monitor, drove the quarterly beat. Shares rose 22.55% to $12.01 on the results and a Raymond James upgrade to Market Perform from Underperform.

Timeline

  1. Third quarter of 2026: Senseonics reported Q3 results and raised its fiscal 2026 guidance.

  2. September 2026: The stock's 50-day average crossed above its 200-day average in a golden cross.

  3. November 10, 2026: Shares rose 22.55% on the quarterly results and analyst upgrade.

Market Landscape

Senseonics' results point to growing demand for implantable continuous glucose monitors as an alternative to wearable sensors in diabetes care. The company's rapid U.S. growth suggests the implantable format is gaining share in a market long dominated by wearable devices.

Investors tracking medical device stocks may see Senseonics' raised guidance and analyst upgrades as signals of improving fundamentals, though the quarterly loss remains a factor. Shareholders should weigh the 22.55% one-day gain against the company's continued losses and the analyst forecast that sits below the new outlook.

The takeaway

Strong product demand can lift revenue and margins quickly, but a company still posting losses depends on sustaining that momentum. Investors and patients alike should watch whether the margin gains hold in the coming quarters.

Further reading

For more on the economic data behind stories like this, see Economic Indicators.